In conclusion, our study establishes HOXA9 as a critical oncogene in the initiation and progression of glioma, and provides evidences into the mechanisms by which patients with HOXA9-positive GBMs respond poorly to temozolomide and have worse clinical outcomes. Here, HOXA9 is linked to glioma.